MIMS table on SGLT2 inhibitors for treatment of type II diabetes

Table summarises costs of SGLT2 inhibitors (dapagliflozin, empagliflozin and ertugliflozin) per 28 days, combinations studied in clinical trials, and recommendations for use in the elderly and patients with hepatic impairment, as well as cardiovascular and renal benefits.

Source:

Monthly Index of Medical Specialities